Positive results from Acarix study presented at ISPOR, a leading health economics conference


Acarix AB (publ) today announced that the company’s real-life data analysis, made in co-operation with clinics in Germany and Austria, is published as a poster presentation and abstract at ISPOR, the leading European conference for health economics and outcomes research, which is held virtually November 16-19, 2020.

PR_Acarix_ISPOR Eng








About Acarix
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, is Certified Advisor of Acarix.

For more information, please visit